ID

13235

Descripción

Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome; ODM derived from: https://clinicaltrials.gov/show/NCT01795924

Link

https://clinicaltrials.gov/show/NCT01795924

Palabras clave

Versiones (1)
  1. 25/1/16 25/1/16 -
Titular de derechos de autor

CC BY-NC 3.0

Subido en

25 de enero de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Acute Myelogenous Leukemia NCT01795924

Inglés

Eligibility Acute Myelogenous Leukemia NCT01795924

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patient has newly diagnosed aml and refuses or is not eligible for treatment with aggressive chemotherapy and/or sct; or aml and has relapsed or been refractory to prior therapy; or high-risk mds, defined as ipss intermediate-2 (int-2) or ipss high-risk, and refuses or is not eligible for standard or aggressive chemotherapy and sct or prior experimental therapies; or high-risk mds, defined as ipss int-2 or ipss high risk, and has failed or been refractory to deoxyribonucleic acid (dna) hypomethylating agents (azacitidine or decitabine), lenalidomide, standard/aggressive chemotherapy, sct, or prior experimental therapies.
Descripción

AML, MDS

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2]
C3463824
has a bone marrow examination performed within 14 days before baseline (c1d1).
Descripción

bone marrow examination

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0005957
has an ecog performance status score of 0 to 2.
Descripción

ECOG

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
aged between 18 and 75 years, inclusive.
Descripción

age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
has a life expectancy of ≥3 months.
Descripción

life expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
has the following laboratory parameters within 7 days before baseline (c1d1):serum creatinine ≤2 mg/dl; total bilirubin ≤2.0 mg/dl; alanine transaminase (alt) or aspartate transaminase (ast) <3.0×the upper limit of normal (uln); left ventricular ejection fraction (lvef) >40%; forced expiratory volume in 1 second (fev1) >60% of predicted.
Descripción

laboratory parameters

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C1278039
UMLS CUI [3]
C0201836
UMLS CUI [4]
C0201899
UMLS CUI [5]
C0428772
UMLS CUI [6]
C0748133
if a female of child-bearing potential, has a negative serum pregnancy test result within 14 days before baseline and agrees to abstain from heterosexual intercourse or use a barrier method for contraception from 14 days before baseline (c1d1) through 30 days after the last study drug dose.
Descripción

pregnancy, contraception

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0700589
if male, agrees to use a latex condom during any sexual contact with a female of child-bearing potential.
Descripción

contraception

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0700589
able to understand and willing to provide written informed consent.
Descripción

informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
has received prior treatment with pd-616 or low-dose cytarabine.
Descripción

prior treatment with pd-616 or low-dose cytarabine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0010711
has received chemotherapy (except hydroxyurea), biological therapy, radiotherapy or investigational therapy within 4 weeks before baseline (c1d1).
Descripción

chemotherapy (except hydroxyurea), biological therapy, radiotherapy or investigational therapy within 4 weeks before baseline

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1522449
UMLS CUI [3]
C1531518
UMLS CUI [4]
C1875319
has active central nervous system (cns) involvement (documented by radiologic lesions and/or malignant cells in the cerebrospinal fluid [csf]).
Descripción

cns leukemia

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1332884
has acute promyelocytic leukemia (apl, fab m3).
Descripción

APL

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023487
has another active systemic malignancy treated with chemotherapy within 12 months before baseline (c1d1).
Descripción

malignancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
has known human immunodeficiency virus (hiv) infection.
Descripción

HIV

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019682
has active graft-versus-host disease (gvhd).
Descripción

GvHD

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018133
has uncontrolled active infection of any kind. (patients with infections controlled by active antibiotic treatment are eligible).
Descripción

infection

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009450
has significant renal or hepatic disease, uncontrolled or severe cardiovascular or pulmonary diseases, or other uncontrolled medical condition that, based on the investigator's assessment, would compromise the patient's ability to tolerate study treatment or the assessment of treatment response.
Descripción

comorbidity compromising study protocol

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2348563
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
Volver a la parte superior de la página

Similar models

Eligibility Acute Myelogenous Leukemia NCT01795924

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
AML, MDS
Item
patient has newly diagnosed aml and refuses or is not eligible for treatment with aggressive chemotherapy and/or sct; or aml and has relapsed or been refractory to prior therapy; or high-risk mds, defined as ipss intermediate-2 (int-2) or ipss high-risk, and refuses or is not eligible for standard or aggressive chemotherapy and sct or prior experimental therapies; or high-risk mds, defined as ipss int-2 or ipss high risk, and has failed or been refractory to deoxyribonucleic acid (dna) hypomethylating agents (azacitidine or decitabine), lenalidomide, standard/aggressive chemotherapy, sct, or prior experimental therapies.
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2])
bone marrow examination
Item
has a bone marrow examination performed within 14 days before baseline (c1d1).
boolean
C0005957 (UMLS CUI [1])
ECOG
Item
has an ecog performance status score of 0 to 2.
boolean
C1520224 (UMLS CUI [1])
age
Item
aged between 18 and 75 years, inclusive.
boolean
C0001779 (UMLS CUI [1])
life expectancy
Item
has a life expectancy of ≥3 months.
boolean
C0023671 (UMLS CUI [1])
laboratory parameters
Item
has the following laboratory parameters within 7 days before baseline (c1d1):serum creatinine ≤2 mg/dl; total bilirubin ≤2.0 mg/dl; alanine transaminase (alt) or aspartate transaminase (ast) <3.0×the upper limit of normal (uln); left ventricular ejection fraction (lvef) >40%; forced expiratory volume in 1 second (fev1) >60% of predicted.
boolean
C0201976 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
C0201899 (UMLS CUI [4])
C0428772 (UMLS CUI [5])
C0748133 (UMLS CUI [6])
pregnancy, contraception
Item
if a female of child-bearing potential, has a negative serum pregnancy test result within 14 days before baseline and agrees to abstain from heterosexual intercourse or use a barrier method for contraception from 14 days before baseline (c1d1) through 30 days after the last study drug dose.
boolean
C0032961 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
contraception
Item
if male, agrees to use a latex condom during any sexual contact with a female of child-bearing potential.
boolean
C0700589 (UMLS CUI [1])
informed consent
Item
able to understand and willing to provide written informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
prior treatment with pd-616 or low-dose cytarabine
Item
has received prior treatment with pd-616 or low-dose cytarabine.
boolean
C0010711 (UMLS CUI [1])
chemotherapy (except hydroxyurea), biological therapy, radiotherapy or investigational therapy within 4 weeks before baseline
Item
has received chemotherapy (except hydroxyurea), biological therapy, radiotherapy or investigational therapy within 4 weeks before baseline (c1d1).
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C1531518 (UMLS CUI [3])
C1875319 (UMLS CUI [4])
cns leukemia
Item
has active central nervous system (cns) involvement (documented by radiologic lesions and/or malignant cells in the cerebrospinal fluid [csf]).
boolean
C1332884 (UMLS CUI [1])
APL
Item
has acute promyelocytic leukemia (apl, fab m3).
boolean
C0023487 (UMLS CUI [1])
malignancy
Item
has another active systemic malignancy treated with chemotherapy within 12 months before baseline (c1d1).
boolean
C0006826 (UMLS CUI [1])
HIV
Item
has known human immunodeficiency virus (hiv) infection.
boolean
C0019682 (UMLS CUI [1])
GvHD
Item
has active graft-versus-host disease (gvhd).
boolean
C0018133 (UMLS CUI [1])
infection
Item
has uncontrolled active infection of any kind. (patients with infections controlled by active antibiotic treatment are eligible).
boolean
C0009450 (UMLS CUI [1])
comorbidity compromising study protocol
Item
has significant renal or hepatic disease, uncontrolled or severe cardiovascular or pulmonary diseases, or other uncontrolled medical condition that, based on the investigator's assessment, would compromise the patient's ability to tolerate study treatment or the assessment of treatment response.
boolean
C2348563 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial